AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

J. S. de Bono; A. Hansen; A. D. Choudhury; N. Cook; E. I. Heath; C. Higano; M. Linch; J. Martin-Liberal; D. E. Rathkopf; K. B. Wisinski; S. Barry; E. de Bruin; W. Brugger; S. Colebrook; T. Klinowska; M. Moschetta; P. G.S. Mortimer; L. L. Siu; G. Shapiro

doi:10.1093/annonc/mdy284.042

AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

J. S. de Bono, A. Hansen, A. D. Choudhury, N. Cook, E. I. Heath, C. Higano, M. Linch, J. Martin-Liberal, D. E. Rathkopf, K. B. Wisinski, S. Barry, E. de Bruin, W. Brugger, S. Colebrook, T. Klinowska, M. Moschetta, P. G.S. Mortimer, L. L. Siu, G. Shapiro

Research output: Contribution to conference › Abstract › peer-review

Original language	English
Pages	viii291-viii292
DOIs	https://doi.org/10.1093/annonc/mdy284.042
Publication status	Published - 1 Oct 2018

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdy284.042

Cite this

de Bono, J. S., Hansen, A., Choudhury, A. D., Cook, N., Heath, E. I., Higano, C., Linch, M., Martin-Liberal, J., Rathkopf, D. E., Wisinski, K. B., Barry, S., de Bruin, E., Brugger, W., Colebrook, S., Klinowska, T., Moschetta, M., Mortimer, P. G. S., Siu, L. L., & Shapiro, G. (2018). AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). viii291-viii292. https://doi.org/10.1093/annonc/mdy284.042

@conference{8a251cbdea444690b08788836aa767d6,

title = "AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)",

author = "{de Bono}, {J. S.} and A. Hansen and Choudhury, {A. D.} and N. Cook and Heath, {E. I.} and C. Higano and M. Linch and J. Martin-Liberal and Rathkopf, {D. E.} and Wisinski, {K. B.} and S. Barry and {de Bruin}, E. and W. Brugger and S. Colebrook and T. Klinowska and M. Moschetta and Mortimer, {P. G.S.} and Siu, {L. L.} and G. Shapiro",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy284.042",

language = "English",

pages = "viii291--viii292",

}

de Bono, JS, Hansen, A, Choudhury, AD , Cook, N, Heath, EI, Higano, C, Linch, M, Martin-Liberal, J, Rathkopf, DE, Wisinski, KB, Barry, S, de Bruin, E, Brugger, W, Colebrook, S, Klinowska, T, Moschetta, M, Mortimer, PGS, Siu, LL & Shapiro, G 2018, 'AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)', pp. viii291-viii292. https://doi.org/10.1093/annonc/mdy284.042

TY - CONF

T1 - AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

AU - de Bono, J. S.

AU - Hansen, A.

AU - Choudhury, A. D.

AU - Cook, N.

AU - Heath, E. I.

AU - Higano, C.

AU - Linch, M.

AU - Martin-Liberal, J.

AU - Rathkopf, D. E.

AU - Wisinski, K. B.

AU - Barry, S.

AU - de Bruin, E.

AU - Brugger, W.

AU - Colebrook, S.

AU - Klinowska, T.

AU - Moschetta, M.

AU - Mortimer, P. G.S.

AU - Siu, L. L.

AU - Shapiro, G.

PY - 2018/10/1

Y1 - 2018/10/1

U2 - 10.1093/annonc/mdy284.042

DO - 10.1093/annonc/mdy284.042

M3 - Abstract

C2 - 32136669

SP - viii291-viii292

ER -